Table 1.

Clinical characteristics; genotypes; drug resistance mutations of the five patients.

Patient	Age (years)	Sex	CD4+ T cell count (cells/μl)	Viral load (copies/ml)	Duration of taking azvudine (days)	ART regimen	HIV-1 subtype	RT mutations
1	39	Male	4.39	675 000	6	B/F/TAF	CRF01_AE	NRTI mutations: M184I NNRTI mutations: none RT other mutations: G141X;I142E;R143N;Y144I;Q145S;Y146V;E305X
2	26	Male	20.25	923 000	14	Switched from 3TC/DTG to 3TC/DTG+TDF	CRF01_AE	NRTI mutations: M184I NNRTI mutations: none RT other mutations: I142G;Y144L;Q145L;Y146V;E305X
3	40	Male	70.46	2 200 000	4	B/F/TAF	CRF07_BC	NRTI mutations: M184I NNRTI mutations: none RT other mutations: R143M;Y144E;Q145S;Y146V;E305X
4	25	Male	16.43	127 000	5	B/F/TAF	CRF01_AE	NRTI mutations: M184I NNRTI mutations: none RT other mutations: K238X;S251K;Q258H;V261R;N265R;A267GS268R;I270F
5	53	Male	14.63	2 740 000	3	B/F/TAF	CRF01_AE	NRTI mutations: M184I NNRTI mutations: none RT other mutations: L289∗;T290Q;E2911;V292∗;I293S;L295S

3TC, lamivudine; ART, antiretroviral therapy; B, bictegravir; DTG, dolutegravir; F, emtricitabine; GRT, genotypic resistance testing; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; RT, reverse transcriptase; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil.